Thomas W. Martens, MD
Medical Director, International Diabetes Center and Internal Medicine, Park Nicollet Clinic
About

Dr. Thomas W. Martens is a board-certified staff internist at Park Nicollet Clinic in Minneapolis, MN, and serves as a medical director at the International Diabetes Center at Park Nicollet Clinic and HealthPartners Care Group, as well as a research investigator at HealthPartners Institute. In addition to maintaining an active internal medicine practice, he serves as principal investigator or co-investigator on a number of ongoing hybrid closed-loop insulin delivery studies, as well as studies involving the use of continuous glucose monitoring (CGM) technology in Type 2 diabetes. He is particularly interested in the translational aspects of implementing diabetes technology in a primary care setting and has presented locally and nationally on the use and interpretation of CGM data in primary care.

Dr. Martens attended medical school at the University of Wisconsin and completed an Internal Medicine residency and chief residency year at Hennepin County Medical Center in Minneapolis, MN. 

Conducting Institute research since 2015.

Current positions:
Medical Director, International Diabetes Center
Research Investigator, HealthPartners Institute
Consultant in Internal Medicine, Park Nicollet Clinic Brookdale Office

Education and training: 
University of Wisconsin Medical School 2001
Residency in Internal Medicine, Hennepin County Medical Center 2005
Fellow of the American College of Physicians 2008

Affiliations/other offices held:
Consultant in Internal Medicine, Park Nicollet Clinic Brookdale Office
Attending physician, Methodist Hospital, St. Louis Park, Minnesota

Research interests include:
Clinical aspects of type 2 diabetes mellitus (T2D) management, quality improvement in the management of T2D. Translation and implementation of diabetes technology into clinical practice. Ambulatory Glucose Profile and continuous glucose monitor (CGM) based management of diabetes. Diabetes technology.

Current research activities and funding:
Principal investigator (PI) for the Patient Centered Outcomes Research Institute (PCORI)-fundedComparing Fingerstick Blood Glucose Monitoring versus Continuous Glucose Monitoring in Primary Care: The GluCoCare Study, which is evaluating the use of BGM and CGM based monitoring in the management of T2D for individuals using insulin to manage diabetes in primary care settings.

Principal Investigator: Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes. Funded by Abbott Diabetes Care.

Co-investigator of multiple industry-funded diabetes technology and medication trials evaluating hybrid closed-loop insulin delivery systems, new analog insulins, and analog insulin-GLP 1 RA medications.

Related websites  
https://orcid.org/0000-0002-9858-2138; https://www.researchgate.net/scientific-contributions/Thomas-W-Martens-2158267477

Affiliation
positions
  • Sr. Research Investigator, Diabetes
  • Medical Director, International Diabetes Center, International Diabetes Center 2015 -
  • Publications While At HealthPartners
    selected publications
    Journal Article
  • -cell function over time on glycemic outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): differential treatment effects of dual therapy
    Diabetes care. 2024
  • Expert panel recommendations for a standardized ambulatory glucose profile report for connected insulin pens
    Diabetes Technology & Therapeutics. 2024
  • The use of rescue insulin in the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)
    Diabetes care. 2024
  • Roadmap to the effective use of continuous glucose monitoring in primary care
    Diabetes Spectrum. 2023
  • How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: findings from the first investigation with the Omnipod® 5 System
    Diabetes Research and Clinical Practice. 2022
  • How use of continuous glucose monitoring can address therapeutic inertia in primary care
    Postgraduate Medicine. 2022
  • Continuous glucose monitoring and glycemic control in patients with type 2 diabetes treated with basal insulin-reply
    JAMA. 2021
  • Continuous glucose monitoring integration for remote diabetes management: virtual diabetes care with case studies
    Diabetes Technology & Therapeutics. 2021
  • Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial
    JAMA. 2021
  • Effect of professional CGM (pCGM) on glucose management in type 2 diabetes patients in primary care
    Journal of Diabetes Science and Technology. 2021
  • Glycaemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data
    Diabetes, Obesity & Metabolism. 2021
  • Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C)
    Postgraduate Medicine. 2021
  • Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes
    Diabetes care. 2021
  • The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin
    Diabetes care. 2021
  • Trial of a new diabetes education model: closing the gap in health disparity for people with diabetes
    Journal of Diabetes Science and Technology. 2021
  • International Diabetes Center: COVID-19 won't stop us from fulfilling our mission
    Journal of Diabetes Science and Technology. 2020
  • Contact
    full name
  • Thomas W. Martens, MD
  • Quick Info
     
    Collaboration
    More Info